Equities

Nath Bio-Genes (I) Ltd

NATHBIOGEN:NSI

Nath Bio-Genes (I) Ltd

Actions
Consumer Staples Food Producers
  • Price (INR)214.18
  • Today's Change-2.82 / -1.30%
  • Shares traded11.33k
  • 1 Year change-1.21%
  • Beta1.8779
Data delayed at least 15 minutes, as of Sep 20 2024 10:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments77438042
Total Receivables, Net1,0211,322203
Total Inventory3,9193,5024,453
Prepaid expenses2.903.603.48
Other current assets, total------
Total current assets5,7175,2084,702
Property, plant & equipment, net2,4062,3402,329
Goodwill, net------
Intangibles, net88104120
Long term investments605051
Note receivable - long term518215211
Other long term assets13106.86
Total assets8,8027,9287,419
LIABILITIES
Accounts payable433277551
Accrued expenses----11
Notes payable/short-term debt1,0411,041916
Current portion long-term debt/capital leases147.307.09
Other current liabilities, total1,137839482
Total current liabilities2,6242,1651,967
Total long term debt494.036.65
Total debt1,1031,052930
Deferred income tax------
Minority interest--(0.2)--
Other liabilities, total302826
Total liabilities2,7032,1961,999
SHAREHOLDERS EQUITY
Common stock190190190
Additional paid-in capital1,3351,3351,335
Retained earnings (accumulated deficit)4,5714,2133,901
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total3.30(5.98)(6.18)
Total equity6,0995,7325,420
Total liabilities & shareholders' equity8,8027,9287,419
Total common shares outstanding191919
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.